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Objectives: Recent experimental studies have suggested that enriching
cardioplegic solution with L-arginine improves myocardial protection
by increasing nitric oxide production. Nitric oxide, however, also gener-
ates the toxic oxygen-derived free radical peroxynitrite; thus these ben-
eficial effects may be dose dependent, especially in vulnerable (stressed)
hearts. Methods: Fifteen neonatal piglets underwent 60 minutes of venti-
lator hypoxia (inspired oxygen fraction 8%-10%) followed by 20 min-
utes of normothermic ischemia on cardiopulmonary bypass (stress).
They were then protected for 70 minutes with multiple doses of blood
cardioplegic solution. In 5 (group 1), the cardioplegic solution contained
no L-arginine, in 5 (group 2), it was enriched with a 4 mmol/L concen-
tration of L-arginine, and in 5 (group 3), a 10 mmol/L concentration of
L-arginine. Myocardial function was assessed by means of pressure vol-
ume loops and expressed as a percentage of control, and coronary vas-
cular resistance and conjugated diene production were measured dur-
ing infusions of cardioplegic solution. Results: Compared with the
protection afforded by blood cardioplegic solution without L-arginine
(group 1), the addition of a 4 mmol/L concentration of L-arginine (group
2) significantly improved myocardial protection, resulting in complete
return of systolic function (end-systolic elastance 38% vs 100%; P < .001
vs 4 mmol/L L-arginine) and preload recruitable stroke work (40% vs
100%; P < .001 vs 4 mmol/L L-arginine); minimal increase in diastolic
stiffness (239% vs 158%; P < .001 vs 4 mmol/L L-arginine); and lower
coronary vascular resistance, conjugated diene production, and
myeloperoxidase activity (P < .001 vs 4 mmol/L L-arginine in each case).
Conversely, supplementing the cardioplegic solution with a 10 mmol/L
dose of L-arginine (group 3) negated these beneficial effects, resulting in
depressed systolic function (end-systolic elastance 41% ± 2%; P < .001
vs 4 mmol/L L-arginine) and preload recruitable stroke work (40% ±
2%; P < .001 vs 4 mmol/L L-arginine); increased diastolic stiffness (246%
± 7%; P < .001 vs 4 mmol/L L-arginine); and higher conjugated diene
production, myeloperoxidase activity, and coronary vascular resistance
(P < .001 vs 4 mmol/L L-arginine in each case). Conclusions: Enriching
cardioplegic solution with a 4 mmol/L concentration of L-arginine signif-
icantly improves myocardial protection by reducing oxygen-derived free
radical formation by white blood cells, thus preserving vascular and
myocardial function. However, these beneficial effects are dose depen-
dent because 10 mmol/L concentrations of L-arginine increase oxygen-
derived free radical production, resulting in vascular and myocardial
dysfunction. (J Thorac Cardiovasc Surg 1999;118:655-64)
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R ecent studies have suggested that enriching cardio-plegic solutions with the amino acid L-arginine
may improve myocardial protection by increasing
nitric oxide production.1-4 Nitric oxide induces vasodi-
latation, which improves cardioplegic distribution, and
reduces endothelial cell adherence of activated white
blood cells (WBCs), thus preventing a leukocyte-medi-
ated injury.1-7 Because nitric oxide levels are depressed
after ischemia, and hypoxia and ischemia both increase
leukocyte adherence during reperfusion, L-arginine
should be most effective in stressed (hypoxic or is-
chemic) hearts.1-3,5,6 However, stressed hearts are more
vulnerable to injury with reperfusion because they are
less able to tolerate a further insult.3,8-12 Increased pro-
duction of nitric oxide could therefore be potentially
harmful, since nitric oxide also generates the toxic oxy-
gen-derived free radical peroxynitrite.2,5,6,13,14 This
may explain why other studies have demonstrated an
increase in myocardial injury with L-arginine, which is
prevented by inhibiting nitric oxide production.2,13-15
The beneficial effects of nitric oxide (L-arginine) may
therefore be dose dependent, especially in vulnerable
stressed hearts. This study uses hypoxic-ischemic
(stressed) neonatal hearts to investigate (1) whether L-
arginine improves myocardial protection in neonates
and (2) whether L-arginine (nitric oxide) has a specific
dose response.
Methods
Twenty-five neonatal (5-18 days old) piglets (3.5-5 kg)
were premedicated with ketamine (40 mg/kg) intramuscular-
ly and anesthetized with phenobarbital (30 mg/kg) intraperi-
toneally, followed by 5 mg/kg intravenously each hour. The
lungs were ventilated via a tracheotomy with a volume venti-
lator (Servo 900B, Siemens/Elema, Solna, Sweden). All ani-
mals received humane care in compliance with the
“Principles of Laboratory Animal Care,” formulated by the
National Society for Medical Research, and the “Guide for
the Care and Use of Laboratory Animals” prepared by the
Institute of Laboratory Animal Resources, National Research
Council, and published by the National Academy Press,
revised 1996. The experimental preparation, including cannu-
lation for cardiopulmonary bypass (CPB), the CPB prime,
and blood sample procurement, is comparable with that pre-
viously described.9,10
Experimental protocols 
Hypoxic-ischemic injury. All piglets underwent 60 minutes
of ventilator hypoxia by lowering the fraction of inspired
oxygen to 8% to 10%, producing an arterial PO2 of 25 to 35
mm Hg and an oxygen saturation of 65% to 70%. Before
hypoxemia, piglets were given transfusions as necessary to
increase their hematocrit value to greater than 35%. This sim-
ulates the chronic adaptive change of erythrocytosis and in-
creases oxygen-carrying capacity, thereby allowing ischemia
to be avoided during hypoxia.9,10,16 At the end of 60 minutes,
piglets were placed on CPB at an inspired oxygen fraction
of 100% for 5 minutes to produce a reoxygenation
injury.9,10,16-18 The aorta was then clamped for 20 minutes at
37°C to add a normothermic ischemic injury to the hypoxic
stress. Ten piglets served as controls for the hypoxic-ischemic
stress. Five underwent myocardial biopsy to determine the
biochemical changes, and the other 5 had the aortic clamp
removed and CPB continued for 60 minutes without further
ischemia to determine the functional changes. The other 15
piglets underwent 70 minutes of cardioplegic arrest accord-
ing to the protocol described below.
Administration of cardioplegic solution. Cardioplegic
solutions (CAPS Service, Research Medical Inc, Salt Lake
City, Utah) are shown in Tables I and II. After the hypoxic-
ischemic insult, piglets underwent 70 minutes of cardioplegic
arrest. The protocol consisted of 5 minutes of warm (37°C)
induction (Table I) followed by 4 minutes of cold multidose
cardioplegia (Table II), a 2-minute cold multidose infusion
every 20 minutes, and a 4-minute warm (37°C) cardioplegic
reperfusate (“hot shot”) before aortic unclamping. Cardio-
plegic solution was always infused at a continuously mea-
sured aortic root pressure of 40 to 50 mm Hg. Immediately
after cardioplegia was started, piglets were cooled to a sys-
temic temperature of 26°C, and warming to 37°C was begun
16 minutes before aortic unclamping. All piglets undergoing
cardioplegic arrest were weaned from CPB with no inotropic
support 30 minutes after aortic unclamping. Final functional
and biochemical measurements were made 30 minutes after
arterial blood gas, Ca2+, and K+ levels were normalized.
Cardioplegia groups. The 15 piglets undergoing cardio-
plegic arrest were divided into 3 groups.
Unmodified blood cardioplegic solution (group 1). In 5
piglets, the blood cardioplegic solution was not supplement-
ed with L-arginine.
Low-dose L-arginine (group 2). In 5 piglets, the blood car-
dioplegic solution was enriched with low-dose L-arginine (4
mmol/L).
High-dose L-arginine (group 3). In the final 5 piglets, the
blood cardioplegic solution was enriched with high-dose L-
arginine (10 mmol/L).
Myocardial oxygen consumption. After cardioplegic
arrest, blood was obtained at 1-minute intervals from the car-
dioplegia line and coronary sinus over the 5 minutes of warm
cardioplegic induction (groups 1 to 3), and myocardial oxy-
gen consumption was calculated as previously described.20
The cumulative 5-minute myocardial oxygen consumption
was determined by the sum of the individual 1-minute values
and expressed per 100 g of heart tissue, which was deter-
mined by weighing the left ventricle at the conclusion of the
experiment.
Myocardial performance. Left ventricular (LV) pressure
and conductance catheter signals were amplified and digi-
tized to inscribe LV pressure volume loops after first correct-
ing for parallel conductance (myocardial tissue and blood
viscosity) with the use of hypertonic saline solution accord-
ing to the method of Baan, Van Der Velde, and Steendijk.20
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The conductance catheter affords a very accurate technique
for measuring instantaneous changes in ventricular volume in
the small heart.21 A series of pressure volume loops was gen-
erated by transient occlusion of the inferior vena cava during
an 8-second period of apnea. Measurements were made
before hypoxia (baseline) and 30 minutes after CPB was dis-
continued. The end-systolic and end-diastolic pressure vol-
ume relationships, as well as preload recruitable stroke work,
were analyzed with the use of a computer graphics program
(Spectrum, Bowman-Gray School of Medicine, Winston-
Salem, NC) on a 486-33 MHz Dell personal computer (Dell
Computer Corporation, Round Rock, Tex). LV systolic per-
formance was determined from the descending slope of the
end-systolic pressure volume relationship by means of linear
regression analysis and designated as end-systolic elastance.
End-diastolic compliance was determine from the exponen-
tial regression of the end-diastolic pressure volume relation-
ship. Global myocardial performance was assessed by pre-
load recruitable stroke work, which was calculated as the
integral of LV transmural pressure and cavity volume over
each cardiac cycle. Functional measurements are expressed
as absolute measurements as well as percent recovery of
baseline values, with each piglet acting as its own control.
After final hemodynamic measurements, all piglets were
placed back on CPB and their hearts arrested with cold (4°C)
blood cardioplegic solution. Transmural LV biopsy speci-
mens were obtained. Endocardial and epicardial portions
were separated, frozen quickly in liquid nitrogen, and stored
for biochemical analysis. A separate sample was obtained to
measure myocardial water.
Physiologic measurements. Coronary vascular resistance
(CVR) was determined during each cardioplegic infusion by
measuring coronary sinus pressure and cardioplegic flow
once a constant infusion rate with an aortic root pressure
between 40 and 50 mm Hg was achieved. CVR was calculat-
ed as previously described as the change in pressure across
the coronary vascular bed, divided by the cardioplegia flow
rate, multiplied by 80, and expressed as dynes · sec · cm–5.9,10
Biochemical analysis 
Adenosine pool. Myocardial samples were crushed in a liq-
uid nitrogen–cooled mortar and pestle and lyophilized
(Savant Speed Vac Systems, Farmingdale, NY). The adeno-
sine pool was determined as described previously according
to the method of Sarin and associates.9,10,22 ATP levels are
expressed as micrograms per gram of dry tissue.
Myeloperoxidase activity. Quantitative myeloperoxidase
activity was determined as described previously by means of
the modified procedures of Okabayashi,23 Halldorsson,24 and
their associates. Enzyme activity is expressed as the change
in optical density units per minute per milligram of tissue
protein (D OD/min/mg protein).
Antioxidant reserve capacity. Myocardial antioxidant
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Table I. Warm blood cardioplegic solution
Volume added Component Concentration 
Cardioplegia additive (mL) modified delivered*
KCl (2 mEq/mL) 10 K+ 8-10 mEq/L
THAM (0.3 mol/L) 225 pH pH 7.5-7.7
CPD 225 Ca2+ 0.2-0.3 mmol/L
Aspartate/glutamate 250 Substrate 13 mmol/L each
D50W 40 Glucose <400 mg/dL
D5W 200 Osmolarity 380-400 mOsm
L-Arginine† 50 Nitric oxide 4 mmol/L (group 2)
10 mmol/L (group 3)
THAM, Tromethamine; CPD, citrate-phosphate-dextrose; D50W, 50% dextrose in water; D5W, 5% dextrose in water.
*When mixed in a 4:1 ratio with blood.
†L-Arginine was mixed in D5W (50 mL). In group 2, 20 mmol of L-arginine was added to the D5W, and in group 3, 50 mmol.
Table II. Cold multidose blood cardioplegic solution
Volume added Component Concentration 
Cardioplegia additive (mL) modified delivered*
KCl (2 mEq/mL) 10 K+ 8-10 mEq/L
THAM (0.3 mol/L) 200 pH pH 7.6-7.8
CPD 50 Ca2+ 0.5-0.6 mmol/L
D5W 1⁄4 NS 550 Osmolarity 340-360 mOsm
L-Arginine† 50 Nitric oxide 4 mmol/L (group 2)
10 mmol/L (group 3)
THAM, Tromethamine; CPD, citrate-phosphate-dextrose; D5W, 5% dextrose in water; NS, normal saline solution.
*When mixed in a 4:1 ratio with blood.
†L-Arginine was mixed in D5W (50 mL). In group 2, 17 mmol of L-arginine was added to the D5W, and in group 3, 43 mmol.
reserve capacity was assessed as previously described by
determining the in vitro lipid peroxidation in cardiac tissue
that was homogenized and incubated with t-butylhydroperox-
ide at a concentration of 4 mmol/L.16,25 Antioxidant reserve
capacity is expressed as malondialdehyde production in
nanomoles per gram of protein of heart tissue. The higher the
production of malondialdehyde to the oxidant stress (t-butyl-
hydroperoxide), the lower the tissue antioxidant reserve
capacity, indicating depletion of antioxidants caused by
exposure of the heart to oxygen-derived free radicals during
reperfusion.
Production of conjugated dienes. Myocardial conjugated
dienes were assessed according to the modified method of
Corongiu and Banni.26 Blood was obtained from the cardio-
plegia line and coronary sinus 1 and 5 minutes after the start
of warm cardioplegia induction. Whole blood samples were
centrifuged at 1000g and frozen at –70°C. Conjugated dienes
are stable at -20°C. Two hundred microliters of plasma was
then extracted with 7 mL of 2:1 chloroform and methanol
(vol/vol), mixed vigorously for a minute or two, and then cen-
trifuged at 1800 rmp for 10 minutes. The 5 mL of organic
layer (Lower) was washed and mixed with 2 mL of 0.003
MHCl. The mixture was centrifuged at 1800 rmp for 10 min-
utes. The organic layer was dried (near dryness) under N2
current with the Fisher sample concentrator model 190
(Fisher Scientific, Pittsburgh, Pa), and then the dried materi-
al was resuspended in 1 mL of hexane. After being mixed, the
sample was read at 233 nm, subtracting a hexane blank. The
same suspension was also scanned between 200 and 325 nm.
The more sensitive second derivative (D2) was then measured
at 237 nm (x), 242 nm (x´), 246 nm (y), 251 nm (y´), from the
scan between 200 to 325 nm. Using the second derivative
formula, conjugated dienes (CD) were calculated as CD = (x
– x´) + (y – y´). Conjugated diene production across the
myocardium at 1 and 5 minutes was then calculated as fol-
lows:
CDp (OD/mL/min) = [(CDcs – CDa) · 5] · CFR
where CDp = conjugated diene production, OD = optical den-
sity, CDa = conjugated dienes in cardioplegic solution, CDcs
= conjugated dienes in coronary sinus, and CFR = cardiople-
gia flow rate.
Production of conjugated dienes was expressed per 100 gm
heart tissue by weighing the left ventricle at the conclusion of
the experiment.
Myocardial water. Ventricular samples were placed in
preweighed vials and dried to a constant weight at a temper-
ature of 85°C. The percent myocardial water was calculated
by means of the following formula:
Statistics. Data were analyzed with JMP V2.0 software
(SAS Institute, Inc, Cary, NC) on a Macintosh IIVX comput-
er (Apple Inc, Cupertino, Calif). The paired Student t test and
1-way analysis of variance were used for comparison of vari-
ables among experimental groups. If the analysis of variance
revealed a significant interaction, pair-wise tests of individual
group means were compared by means of multiple compar-
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Table III. Left ventricular function
End-systolic elastance Diastolic compliance Preload recruitable stroke work
c % b % Control c % 
Group Intercept Slope* Recovery Coefficient stiffness Intercept Slope† Recovery
Hypoxic-ischemic stress
Baseline 6.4 ± 0.2 35 ± 2 — 0.04 ± 0.02 — 10.7 ± 0.3 67 ± 3 —
Postbypass — — — — — — — —
Unmodified blood
cardioplegia (group 1)
Baseline 6.5 ± 0.1 34 ± 2 — 0.04 ± 0.01 — 10.6 ± 0.3 66 ± 3 —
Postbypass 6.7 ± 0.2 14 ± 2 41% ± 2% 0.1 ± 0.02 267% ± 7% 10.5 ± 0.1 26 ± 3 39% ± 2%
L-Arginine: 4 mmol/L
(group 2)
Baseline 6.3 ± 0.2 36 ± 1 — 0.05 ± 0.02 — 10.8 ± 0.1 69 ± 3 —
Postbypass 6.5 ± 0.1 36 ± 2 100% ± 2%‡ 0.08 ± 0.01 160% ± 4%‡ 10.7 ± 0.3 69 ± 2 100% ± 2%‡
L-Arginine: 10 mmol/L 
(group 3)
Baseline 6.4 ± 0.1 35 ± 2 — 0.04 ± 0.02 — 10.7 ± 02 68 ± 2 —
Postbypass 6.6 ± 0.2 15 ± 1 42% ± 2% 0.1 ± 0.01 259% ± 6% 10.6 ± 0.2 28 ± 3 41% ± 2%
F = 2341 F = 209 F = 601
P < .001 P < .001 P < .001
c Intercepts expressed in mL.
*End-systolic elastance slope expressed in mm Hg/mL.
†Preload recruitable stroke work slope expressed as [∫(mm Hg · mL)/mL].
‡P < .001 versus groups 1 and 3.
% Myocardial water = (Wet weight –  Dry weight)
Wet weight · 100
isons (Tukey’s test) using a level of significance of P < .05, P
< .01, and P < .001. Group data are expressed as mean ± stan-
dard error of the mean.
Results
There was no significant difference (P > .2) between
groups for baseline (pre-hypoxic) values of LV con-
tractility (35 ± 2), diastolic compliance (0.04 ± 0.01),
or preload recruitable stroke work (68 ± 3). All piglets
tolerated 60 minutes of hypoxia with stable hemo-
dynamics.
Hemodynamic and physiologic measurements.
Results are depicted in Table III and Figs 1 to 4. There
was no significant change or difference (P > .2) in the
X-axis intercept for end-systolic elastance or preload
recruitable stoke work between prebypass (baseline)
and postbypass values in any cardioplegia group.
Therefore, the change in slope of end-systolic elastance
and preload recruitable stroke work can be interpreted
to express variability in the contractile state of the
myocardium compared with baseline values. This
allows the change in slope to be expressed as a per-
centage of baseline with each piglet to act as its own
control. The combination of hypoxia and ischemia
caused such a severe injury that CPB could not be dis-
continued in piglets not receiving cardioplegia (hypox-
ic-ischemic controls), despite an additional 60 minutes
of CPB support. Therefore no postbypass functional
measurements could be obtained in these piglets. In
contrast, blood cardioplegic solution without L-argi-
nine (group 1) was able to partially resuscitate the
hypoxic-ischemic myocardium, thereby allowing CPB
to be discontinued. However, these piglets still had
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Fig 1. Recovery of LV systolic function as measured by end-
systolic elastance (EES) and expressed as percentage of con-
trol (baseline). Note: Exposing the heart to hypoxia and
ischemia produces such a severe stress that unmodified aspar-
tate-glutamate blood cardioplegic solution is unable to fully
resuscitate the heart. In contrast, cardioplegic solution
enriched with a 4 mmol/L concentration of L-arginine is able
to fully resuscitate the hypoxic myocardium, resulting in
complete return of systolic function. Conversely, these bene-
ficial effects were negated if the L-arginine concentration was
increased to 10 mmol/L. *P < .001 (mean ± standard error).
Fig 2. Postbypass LV diastolic compliance as measured by
the end-diastolic pressure volume relationship and expressed
as percentage of stiffness compared with control (baseline).
Note: There is a marked increase in diastolic stiffness in
hearts given unmodified blood cardioplegic solution.
Conversely, enriching the cardioplegic solution with a 4
mmol/L concentration of L-arginine allowed for cellular
repair of the hypoxic-ischemia injury, improving diastolic
compliance. This beneficial effect was lost if the dose of L-
arginine was increased to 10 mmol/L. *P < .001 (mean ±
standard error). BCP, Blood cardioplegic solution.
Fig 3. Recovery of overall myocardial function as measured
by preload recruitable stroke work (PRSW) and expressed as
percentage of control (baseline). *P < .001 (mean ± standard
error).
depressed postbypass systolic contractility, markedly
increased diastolic stiffness, and reduced preload re-
cruitable stroke work. In contrast, cardioplegic solution
supplemented with low-dose L-arginine (4 mmol/L,
group 2) fully resuscitated and protected the severely
stressed (hypoxic-ischemic) myocardium, resulting in
complete return of systolic function and preload
recruitable stroke work and minimal increase in dias-
tolic stiffness. However, if the L-arginine concentration
was increased to 10 mmol/L (group 3), these beneficial
effects were negated, resulting in depressed systolic
function, markedly increased diastolic stiffness, and
reduced preload recruitable stroke work. CVR followed
a similar trend, with low-dose L-arginine (4 mmol/L,
group 2) resulting in lower CVR than either blood car-
dioplegia without L-arginine (group 1) or high-dose L-
arginine (10 mmol/L, group 3).
Biochemical studies. Results are summarized in
Table IV. Compared with levels at the end of the hypox-
ic-ischemic stress, blood cardioplegic solution without
L-arginine (group 1) improved the biochemical markers
of injury. However, a significant oxygen-derived free
radical reperfusion injury was documented by the high
production of conjugated dienes and decreased tissue
antioxidant reserve capacity. The myeloperoxidase
activity was increased, and the adenosine triphos-
phate/diphosphate ratio (ATP/ADP ratio), which mea-
sures the ability of the mitochondria to phosphorylate
ADP to ATP and is an indirect measurement of mito-
chondrial function, was decreased. Mitochondrial dys-
function (low ATP/ADP ratio) then prevented replen-
ishment of ATP levels. In contrast, supplementing the
cardioplegic solution with low-dose L-arginine (4
mmol/L, group 2) significantly decreased the produc-
tion of oxygen-derived free radicals during reperfusion
(low conjugated dienes and high antioxidant reserve
capacity). This preserved mitochondrial function (nor-
mal ATP/ADP ratio), allowing replenishment of ATP
levels, and explains the significantly higher myocardial
oxygen consumption during warm cardioplegic induc-
tion. This reduction of injury correlated with a reduc-
tion in the myeloperoxidase activity. Conversely, high-
dose L-arginine (10 mmol/L, group 3) increased the
production of oxygen-derived free radicals (high con-
jugated dienes and low antioxidant reserve capacity),
resulting in increased cellular injury, impaired meta-
bolic recovery, and increased WBC accumulation
(myeloperoxidase activity). The myocardial water
(edema), which is an indirect measurement of cellular
injury, was reduced with low-dose L-arginine (group 2),
further supporting a decreased cellular injury in these
hearts.
Discussion
The role of nitric oxide in myocardial protection
remains controversial, because some reports demon-
strate beneficial effects by enhancing production (L-
arginine), whereas others demonstrate a benefit to
reducing production.2,3,5,6,13-15 These differences may
be related to many factors, including the model used in
the investigation, pathologic states of the myocardium,
and the dosage of L-arginine. This study attempts to
clarify the effects of L-arginine and nitric oxide pro-
duction using an in vivo preparation that mimics the
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Fig 4. Coronary vascular resistance (CVR) measured during cardioplegic infusion once the flow and cardioplegic
pressures were stable. *P < .001 (mean ± standard error).
operative setting to avoid conflicting results that may
not be clinically applicable. It also uses stressed hearts
because they are the most difficult to protect, as well as
the most vulnerable to further injury. The present study
demonstrates the following: (1) The hypoxic-ischemic
stress causes a severe injury; (2) blood cardioplegic
solution without L-arginine is incapable of fully resus-
citating or protecting the severely stressed (hypoxic-
ischemic) neonatal heart; (3) supplementing the blood
cardioplegic solution with low-dose L-arginine mark-
edly improves myocardial protection by decreasing
oxygen-derived free radical formation during reperfu-
sion, preventing neutrophil accumulation, and preserv-
ing vascular function, resulting in complete return of
myocardial contractility; and (4) increasing the dosage
of L-arginine in blood cardioplegic solution nullifies
these beneficial effects by increasing the formation of
oxygen-derived free radicals during reperfusion, result-
ing in vascular dysfunction and depressed functional
recovery.
In the presence of the enzyme nitric oxide synthase,
the nonessential amino acid L-arginine combines with
oxygen to produce nitric oxide and citrulline.1,3,5,6,14
Nitric oxide then reacts with the vascular endothelium,
resulting in vasorelaxation, decreased platelet and
WBC adherence, reduced chemotaxis of WBCs, and
neutralization of superoxide radicals.1,2,5,6 In the pres-
ence of ischemia or hypoxia, reperfusion causes
endothelial cell dysfunction with impaired release of
nitric oxide.3,5,6,17,18,27 This may predispose the tissue
to an exacerbated reperfusion injury caused by unscav-
enged oxygen-derived free radicals, vasoconstriction,
and increased WBC and platelet adherence.1,3,5-7,17 The
benefits of L-arginine supplementation of cardioplegic
solutions is predicated on incorporating the nitric oxide
precursor into endothelial cells with subsequent pro-
duction and release of nitric oxide. Supplemental L-
arginine is indeed taken up by vascular endothelial
cells, and the enhanced uptake results in increased pro-
duction of nitric oxide.28 This explains why under cer-
tain conditions enriching cardioplegic solution with L-
arginine improves myocardial protection, reduces
necrosis, and preserves endothelial cell function after
cardioplegic arrest.1-4
Neonatal hearts in this study were subjected to both
ischemia and hypoxia before cardioplegic arrest, where-
as most of our previous studies have subjected the
neonatal heart to either hypoxia or ischemia, but not
both.8-10,16 We combined these 2 stresses because (1)
blood cardioplegia without L-arginine is so effective that
it results in complete return of function in neonatal
hearts subjected to hypoxia alone9,10,30 and (2) this
injury may more closely mimic the condition of the
chronically cyanotic infant. This is because our model
of acute hypoxia does not result in ischemia, whereas
chronically hypoxic infants are subject to ischemia with
ATP depletion during periods of acute stress.9-11,16,29-31
This probably explains why cyanotic infants often have
depressed myocardial function after apparently success-
ful surgical repair and provides an explanation of why
we saw greater production of oxygen-derived free radi-
cals in cyanotic infants than in animals subjected to
acute hypoxia.11,12,16,25,31,32 However, even if our model
does not completely mimic the clinical situation, it does
subject the heart to a severe stress. This is important,
because most neonatal hearts undergoing surgery are
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Table IV. Myocardial oxygen consumption and biochemical results
MVO2* CD production
* ARC† ATP Myocardial MPO 
(mL/100 gm/ (OD/mL/100 gm/min) (MDA nmol/ (m g/ ATP/ADP water (D OD/min/
Group 5 min) 1 min 5 min g protein) g dry wt) ratio (%) mg protein)
Hypoxic-ischemic stress — — — 1441 ± 24 8.2 ± 0.3 1.1 ± 0.2 80.1 ± 0.2 2.4 ± 0.2
Unmodified blood 6.7 ± 0.3 72 ± 2 74 ± 2 1216 ± 26‡ 10.8 ± 0.6‡ 2.0 ± 0.3‡ 80.7 ± 0.2‡ 1.6 ± 0.1‡
cardioplegia (group 1)
L-Arginine (4 mmol/L) 10.2 ± 0.2§ 20 ± 2§ 21 ± 1§ 858 ± 28§ 16.1 ± 0.4§ 3.8 ± 0.3§ 79.7 ± 0.3§ 0.9 ± 0.1§
(group 2)
L-Arginine (10 mmol/L) 6.9 ± 0.3 74 ± 2 75 ± 2 1234 ± 17‡ 11.8 ± 0.5‡ 1.9 ± 0.2‡ 80.8 ± 0.1‡ 1.8 ± 0.2‡
(group 3)
F = 105 F = 892 F = 49.5 F = 12.0 F = 43.7 F = 201 F = 467 F = 480
P < .001 P < .001 P < .001 P < .001 P < .001 P < .001 P < .001 P < .001
MVO2, Myocardial oxygen consumption; CD, conjugated diene; OD, optical density; ARC, antioxidant reserve capacity; MDA, malondialdehyde; ATP, adenosine
triphosphate; ADP, adenosine diphosphate; MPO, myeloperoxidase.
*During cardioplegia induction (reperfusion).
†MDA production at 4 mmol/L t-butylhydroperoxide.
‡P < .001 versus hypoxic-ischemic stress.
§P < .001 versus all groups.
not “normal,” but are subjected to hypoxia, ischemia, or
a pressure volume overload. Furthermore, it is under
these conditions that inhibitors of nitric oxide (ie, Nw -
nitro-L-arginine methyl ester) have been shown to be
beneficial.2,13-15
The combination of hypoxia and ischemia caused
such a severe stress that blood cardioplegic solution
without L-arginine was unable to fully resuscitate the
neonatal heart. Despite partial improvement, there was
still a substantial increase in the production of oxygen-
derived free radicals. This damaged mitochondria (low
ATP/ADP ratio), which explains the reduced oxygen
uptake during cardioplegic induction, the lower postby-
pass ATP levels, and depressed functional recovery. In
contrast, enriching the cardioplegic solution with low-
dose L-arginine reduced the generation of oxygen-
derived free radicals during reperfusion. This prevented
mitochondrial damage (normal ATP/ADP ratio), allow-
ing replenishment of ATP, increased oxygen uptake
during cardioplegic induction, and improved functional
recovery. The myeloperoxidase activity, which is a
measure of WBC sequestration, was also decreased in
these hearts. This supports previous studies that have
suggested that L-arginine acts primarily by preventing
adherence of WBCs to the vascular endothelium.1,3,4
Once bound, WBCs then release proteases and oxygen-
derived free radicals, resulting in tissue damage.5-7 L-
Arginine, however, may also scavenge oxygen-derived
free radicals directly. The decrease in oxygen radical
production could therefore be due to reduced WBC
activity, neutralization of oxygen-derived free radicals
directly, or both. Increasing the dose of L-arginine,
however, completely negated these beneficial effects.
Oxygen-derived free radical production was increased,
resulting in mitochondrial damage and impaired post-
bypass functional recovery. Therefore, L-arginine
(nitric oxide) has a paradoxic effect. In low concentra-
tions, nitric oxide is beneficial by preventing WBC
adherence, whereas if too much nitric oxide is pro-
duced, these beneficial effects are overwhelmed by the
excess production of the oxygen-derived free radical
peroxynitrite.
Another pathway by which nitric oxide may improve
cardioplegic protection is through vasodilation.1-3,5,6
Perfusion defects can result from increased vascular
resistance as a result of impaired production of nitric
oxide or an increase in the vasoconstrictor endothe-
lin.1,3 This can limit cardioplegic distribution. Low-
dose L-arginine improved cardioplegic distribution by
reducing CVR during infusions of cardioplegic solu-
tion. However, this lower resistance probably denotes
preservation of normal vascular function, and not
vasodilatation, since the coronary vasculature should
be vasodilated after an ischemic stress. Conversely, the
rise in CVR in the other cardioplegic groups (groups 1
and 3) suggests vascular dysfunction with vasocon-
striction. High-dose L-arginine, however, should induce
vasodilation and prevent a WBC injury because of
increased levels of nitric oxide. The increased CVR
with high-dose L-arginine therefore probably repre-
sents a vascular injury from overproduction of perox-
ynitrite. WBCs then migrate into the tissue as a result
of the overwhelming reperfusion injury despite the
decreased adherence caused by nitric oxide (L-arginine).
We cannot prove that an increased CVR denotes a vas-
cular injury, because specific tests of endothelial cell
function were not performed after CPB. It is possible
that the rise in CVR is due to increased cellular edema.
We believe, however, that an increased CVR probably
reflects a vascular injury because (1) the difference in
myocardial water between groups is slight and (2) there
is a direct correlation between oxygen-derived free radi-
cal production, CVR, and functional recovery.
Because this study suggests that L-arginine can be
detrimental, we believe its use in patients may not be
advisable for several reasons:
1. This and other studies reflect the optimal L-argi-
nine dose in animals. Human beings, however, may
have different levels of the enzyme nitric oxide syn-
thase, and so the amount of nitric oxide produced may
be different in patients exposed to a similar concentra-
tion of L-arginine. 
2. There are 2 forms of the enzyme nitric oxide syn-
thase that converts L-arginine to nitric oxide, inducible
and noninducible.1-3,5-7,14 Several physiologic condi-
tions (ie, angina) increase the concentration of
inducible nitric oxide synthase. This may allow greater
quantities of nitric oxide to be produced from a given
concentration of L-arginine.5-7,14
3. The response to nitric oxide may be dependent on
the pathologic state of the myocardium. Hearts subject-
ed to hypoxia or ischemia already generate increased
amounts of oxygen-derived free radicals with reperfu-
sion and may therefore be more sensitive to the toxic
oxygen radical peroxynitrite.8,16,17,27 This would
explain why several studies that examined stressed
(hypoxic or ischemic) hearts demonstrated a benefit
with inhibition of nitric oxide synthesis during reperfu-
sion or reoxygenation.2,13-15
4. Coronary artery disease can lead to maldistribution
of cardioplegic solutions, with some regions of the
myocardium receiving up to 10 times the flow per gram
of muscle compared with other regions.8,33 Increased
delivery of L-arginine–supplemented cardioplegic solu-
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tion to these segments might increase nitric oxide
production. 
5. The dose response must be known under both
hypothermic and normothermic temperatures, because
the conversion of L-arginine to nitric oxide is tempera-
ture dependent. It may therefore be undesirable to use
a substance that has both positive and negative effects,
and a dose response curve that is unknown in human
beings and may change under various conditions. One
cannot ignore, however, the potential beneficial effects
of L-arginine. Until the aforementioned problems can
be addressed, we believe L-arginine should be used
cautiously and that alternative strategies or solutions
that can provide a similar benefit without being poten-
tially harmful should be investigated. 
R E F E R E N C E S
1. Mizuno A, Baretti R, Buckberg GD, Young H, Vinten-Johansen J,
Ma X, et al. Endothelial stunning and myocyte recovery after
reperfusion of jeopardized muscle: a role of L-arginine blood car-
dioplegia. J Thorac Cardiovasc Surg 1997;113:379-89.
2. Hiramatsu T, Forbess J, Miura T, Nomura F, Mayer JE Jr.
Additive effects of L-arginine infusion and leukocyte depletion on
recovery after hypothermic ischemia in neonatal lamb hearts. J
Thorac Cardiovasc Surg 1995;110:172-9.
3. Sato H, Zhao Z, McGee DS, Williams MW, Hammon JW Jr,
Vinten-Johansen J. Supplemental L-arginine during cardioplegic
arrest and reperfusion avoids regional postischemic injury. J
Thorac Cardiovasc Surg 1995;110:302-14.
4. Carrier M, Khalil A, Tourigny A, Solymoss B, Pelletier L. Effect
of L-arginine on metabolic recovery of the ischemic myocardium.
Ann Thorac Surg 1996;61:1651-7.
5. Boyle EM Jr, Pohlman TH, Cornejo CJ, Verrier ED. Ischemia-
reperfusion injury. Ann Thorac Surg 1997;64:S24-30.
6. Verrier ED, Boyle EM Jr. Endothelial cell injury in cardiovascu-
lar surgery: an overview. Ann Thorac Surg 1997;64:S2-8.
7. Boyle EM Jr, Pohlman TH, Johnson M, Verrier ED. Endothelial
cell injury in cardiovascular surgery: the systemic inflammatory
response. Ann Thorac Surg 1997;63:277-84.
8. Buckberg GD, Allen BS. Myocardial protection: management
during adult cardiac operations. In: Baue AE, Geha AS,
Hammond GL, Laks H, Naunheim KS, editors. Glenn’s thoracic
and cardiovascular surgery. 6th ed. Stamford (CT): Appleton &
Lange; 1995. p. 1653-87.
9. Bolling KS, Kronon M, Allen BS, Ramon S, Wang T, Hartz R, et
al. Myocardial protection in normal and hypoxically stressed
neonatal hearts: the superiority of hypocalcemic versus normo-
calcemic blood cardioplegia. J Thorac Cardiovasc Surg 1996;
112:1193-201.
10. Bolling KS, Kronon M, Allen BS, Wang T, Ramon S, Feinberg H.
Myocardial protection in normal and hypoxically stressed neona-
tal hearts: the superiority of blood versus crystalloid cardioplegia.
J Thorac Cardiovasc Surg 1997;113:994-1005.
11. Silverman N, Kohler J, Levitsky S, Pavel D, Fang R, Feinberg H.
Chronic hypoxemia depresses global ventricular function and
predisposes to depletion of high energy phosphates during car-
dioplegic arrest: implications for surgical repair of cyanotic con-
genital heart defects. Ann Thorac Surg 1984;37:304-8.
12. Hammon JW Jr, Graham TP Jr, Boucek RJ Jr, Parrish MD,
Merrill WH, Bender HW Jr. Myocardial adenosine triphosphate
content as a measure of metabolic and functional myocardial pro-
tection in children undergoing cardiac operation. Ann Thorac
Surg 1987;44:467-70.
13. Morita K, Ihnken K, Buckberg GD, Sherman MP, Young HH.
Studies of hypoxemic/reoxygenation injury: without aortic
clamping. V. Role of the L-arginine-nitric oxide pathway. J
Thorac Cardiovasc Surg 1995;110:1200-11.
14. Matheis G, Sherman P, Buckberg G, Haybron D, Young H,
Ignarro L. Role of L-arginine–nitric oxide pathway in myocardial
reoxygenation injury. Am J Physiol 1992;262:H616-20.
15. Schulz R, Wambolt R. Inhibition of nitric oxide synthesis pro-
tects the isolated working rabbit heart from ischemia-reperfusion
injury. Cardiovasc Res 1995;30:432-9.
16. Bolling KS, Halldorsson A, Allen BS, Rahman S, Wang T,
Kronon M, et al. Prevention of the hypoxic reoxygenation injury
with the use of a leukocyte-depleting filter. J Thorac Cardiovasc
Surg 1997;113:1081-90.
17. Buckberg GD. Studies of hypoxemic/rexoygenation injury: I.
Linkage between cardiac function and oxidant damage. J Thorac
Cardiovasc 1995;110:1164-70.
18. Ihnken K, Morita K, Buckberg GD, Sherman MP, Young HH.
Studies of hypoxemic/reoxygenation injury: without aortic
clamping. III. Comparison of the magnitude of damage by
hypoxemia/reoxygenation versus ischemia/reperfusion. J Thorac
Cardiovasc Surg 1995;110:1182-9.
19. Hanafy HM, Allen BS, Winkelmann JM, Ham JW, Osimani D,
Hartz RS. Warm blood cardioplegic induction: an underused
modality. Ann Thorac Surg 1994;58:1589-94.
20. Baan J, Van Der Velde E, Steendijk P. Ventricular pressure vol-
ume relations in vivo. Eur Heart J 1992;13(Suppl E):2-6.
21. Cassidy SC, Teitel DF. The conductance volume catheter tech-
nique for measurement of left ventricular volume in young
piglets. Pediatr Res 1992;31:85-90.
22. Sarin M, Buinevicius Z, Levitsky S, Feinberg H. Isocratic high-
performance liquid chromatographic analysis of myocardial cre-
atine phosphate and adenine nucleotides. J Chromatogr
1991;563:129-33.
23. Okabayashi K, Aoe M, DeMeester SR, Cooper JD, Patterson AG.
Pentoxifyllene reduces lung allograft reperfusion injury. Ann
Thorac Surg 1994;58:50-6.
24. Halldorsson A, Kronon M, Allen BS, Bolling KS, Wang T,
Rahman SK, et al. Controlled reperfusion after lung ischemia:
implications for improved function after lung transplantation. J
Thorac Cardiovasc Surg 1998;115:415-25.
25. Allen BS, Rahman SK, Ilbawi M, Feinberg H, Bolling KS,
Kronon M. The detrimental effects of cardiopulmonary bypass in
cyanotic infants: preventing the reoxygenation injury. Ann
Thorac Surg 1997;64:1381-8.
26. Corongiu F, Banni S. Detection of conjugated dienes by second
derivatives ultraviolet spectrophotometry. Methods Enzymol
1994;233:303-10.
27. Ihnken K, Morita K, Buckberg GD, Matheis G, Sherman MP,
Allen BS, et al. Studies of hypoxemic/reoxygenation injury:
without aortic clamping. II. Evidence for reoxygenation damage.
J Thorac Cardiovasc Surg 1995;110:1171-81.
28. Palmer R, Ashton D, Moncada S. Vascular endothelial cells syn-
thesize nitric oxide from L-arginine. Nature 1988;333:6646.
29. Boucek RJ Jr, Kasselberg AG, Boerth RC, Parrish MD, Graham
The Journal of Thoracic and
Cardiovascular Surgery
Volume 118, Number 4
Kronon et al   663
TP Jr. Myocardial injury in infants with congenital heart disease:
evaluation by creatine kinase MB isoenzyme analysis. Am J
Cardiol 1982;50:129-35.
30. Graham TP Jr, Erath HG Jr, Buckspan GS, Fisher RD. Myocardial
anaerobic metabolism during isoprenaline infusion in a cyanotic
animal model: possible cause of myocardial dysfunction in cyan-
otic congenital heart disease. Cardiovasc Res 1979;13:401-6.
31. Del Nido PJ, Mickle DAG, Wilson GJ, Benson LN, Weisel RD,
Coles JG, et al. Inadequate myocardial protection with cold car-
dioplegic arrest during repair of tetralogy of Fallot. J Thorac
Cardiovasc Surg 1988;95:223-9.
32. Rocchini AP, Keane JF, Castaneda AR, Nadas AS. Left ventricu-
lar function following attempted surgical repair of tetralogy of
Fallot. Circulation 1978;57:798-802.
33. Guyton R, Gott J, Brown W, Craver J. Cold and warm myocar-
dial protection techniques. In: Karp RB, Laks H, Wechsler AS,
editors. Advances in cardiac surgery. St Louis: Mosby–Year
Book; 1996. p. 1-30.
664 Kronon et al The Journal of Thoracic and
Cardiovascular Surgery
October 1999
THE THORACIC SURGERY FOUNDATION FOR RESEARCH AND EDUCATION
Kennedy School Sabbatical
The Thoracic Surgery Foundation for Research and Education announces that applications for a year-long
sabbatical to do graduate studies in health care policy at Harvard University’s Kennedy School of
Government are now available. Candidates will be accepted early on a rolling admission basis by the grad-
uate school, and scholarships will be awarded by The Foundation’s Education Committee. The Kennedy
School will review completed applications for the program starting January 3, 2000, and is prepared to make
decisions on applications within two weeks of their receipt. The Foundation will make a decision on an
application for Alley-Sheridan Scholarship within two weeks of its receipt to The Foundation office. If an
interested surgeon has applied to The Kennedy School very early in January, it is possible to have the admis-
sion and scholarship decisions completed by February 1. Please call Lainie Castle at The Foundation office
for more information at 312-644-6610, extension 4798.
